Daewoong Acquires Stake in US Partner ‘Privatera’
Daewoong Group’s holding company, Daewoong, announced on the 24th that it has obtained 3.46 million shares from its US partner, Privatera Acquisition, for approximately KRW 43.8 billion. This represents 3.4% of Daewoong’s equity capital, bringing its total stake in Privatera to 12.63%. The purpose of this acquisition is to strengthen global partnerships in the treatment business of Daewoong’s botulinum toxin, ‘Nabota’.
Handok Awards Stock Options to Executives and Employees
Handok revealed on the 24th that it will grant 7,550 stock options to 16 executives and employees. The decision to award stock options was made by the board of directors on the 21st. These stock options have an exercise period from July 21, 2028, to July 20, 2033, with an exercise price of KRW 14,000. Following the grant of stock options, the total number of shares issued by Handok will be 240,800 shares.
SK Biopharmaceuticals and SK Life Science Sign Supply Contract for ‘Cenobamate’
SK Biopharmaceuticals announced on the 24th that it has signed a supply agreement with its subsidiary in the United States, SK Bioscience, for ‘Cenobamate’, a new drug used in the treatment of epilepsy. The contract is valued at KRW 36.9 billion and represents an internal transaction that does not contribute to sales based on financial statements.
Vice Chairman Yoon Sang-hyun of Korea Kolmar Holdings Purchases Stock
Yoon Sang-hyun, Vice Chairman of Korea Kolmar Holdings, announced on the 24th that he has made three stock purchases on July 19, 20, and 21. Following these acquisitions, Vice Chairman Yoon now holds 5,431,012 shares, bringing his total holdings to 5,445,158 shares.
Dongsung Pharmaceutical Discloses Results of KRW 14 Billion Bond Issuance
Dongsung Pharmaceutical announced on the 24th that it is issuing bonds with guarantees (BW) worth KRW 14 billion, as decided on the 20th. The issuance follows the exercise of warrants, with a total of 2,381,762 shares being issued. The purpose of this financing is to secure operating funds (KRW 5.5 billion) and repay debts (KRW 8.5 billion). The maturity date for these bonds is July 24, 2028.
Dong-A Socio Holdings and Dong-A ST Announce Settlement Results
Dong-A Socio Holdings and Dong-A ST announced on the 24th that they will disclose their financial results on the 27th. Dong-A Socio Holdings will share its results for the period between January 1 and June 30, 2023, while Dong-A ST will provide results for the period between April 1 and June 30, 2023. It is important to note that the settlement results disclosed are provisional and subject to change as they undergo review by external auditors.
Dong-A Socio Holdings also announced that it will hold a corporate briefing session on the 27th at 4:30 pm. During this session, the company will discuss the business performance and management status of its major related companies in the second quarter of 2023. Likewise, Dong-A ST will hold a company briefing session via conference call at 3:30 pm on the same day, discussing its management performance for the second quarter.
Dong-A Socio Holdings Extends Raw Material Supply Contract with ST Pharm Subsidiary
Dong-A Socio Holdings, a subsidiary of ST Pharm, has responded to a customer’s request for an extension of the delivery date by extending the contract period between July 28, 2023, and August 31, 2023. The contract pertains to the supply of raw materials (oligonucleotide) for the treatment of chronic hepatitis B, which is currently undergoing global phase 2 clinical trials. ST Pharm is the sole raw material supplier, and the new drug is expected to be commercialized by the end of 2024.
PharmAbcine Acquires Bonds Before Maturity Following Bond Issuance with Guarantees
PharmAbcine announced on the 24th that it has acquired pre-maturity bonds after issuing bonds with warrants (BW) through the exercise of put options. The exercise price of these warrants per share is KRW 6,515, and the bonds acquired amount to KRW 2 billion.
Bonds Acquired Before Maturity After Issuing Convertible Bonds
Shillazen announced on the 24th that it has acquired convertible bonds (CB) and bonds before maturity in response to creditors’ request for early repayment. The conversion price per share is KRW 7,030, and the acquired bonds amount to KRW 4.4 billion. The acquisition amount includes the principal and interest paid. The conversion price per share was adjusted from KRW 8,280 to KRW 7,030 on January 24, 2023, reflecting the decrease in the market price.
Labgenomics Approves 100% Bonus Issue
Labgenomics announced on the 24th that it has approved a 100% bonus issue, wherein 1 new share will be allocated for every 1 share of common stock. The total number of new shares issued will be 37,110,995 ordinary shares. The reference date for the allocation of new shares is August 8, and the scheduled listing date for these shares is August 28. Trading of Labgenomics stock on the KOSDAQ Market Headquarters of the Korea Exchange was suspended from 3:39 pm until the end of the market on the same day.
ST Pharm Discloses Settlement Results and Plans Corporate Briefing
ST Pharm announced on the 24th that it will disclose its second quarter results on the 27th, covering the period from April 1st to June 30th. Additionally, the company will hold a corporate briefing through a video conference call on the same day from 4 pm to 4:30 pm. During this briefing, ST Pharm will discuss its 2Q business results and key issues with analysts from domestic and foreign securities companies.
Nexton Bio Decides to Issue Convertible Bonds
Nexton Bio announced on the 24th that it will issue its 6th privately placed convertible unsecured bond (CB) worth KRW 8 billion. Out of this amount, KRW 6 billion will be used for operating funds, and KRW 2 billion will be allocated for the acquisition of securities from other corporations. The conversion price is KRW 8,885, and the conversion claim period is from July 26, 2024, to June 26, 2026. The number of shares issued after conversion will be 900,393, which represents 9.72% of the total number of shares issued.
Anguk Pharmaceutical Terminates Drug Supply Contract with Chinese Pharmaceutical Company
Anguk Pharmaceutical announced on the 24th that it has terminated the supply contract for ‘Anicorp’, a drug worth KRW 26.7 billion, with Sichuan Wanhe Chinese Medicinal Decocting Pieces PLC. This termination represents 18.97% of the recent sales, and it was due to the counterparty’s failure to fulfill the contract.
Green Cross MS Invests in Expansion of Production
Green Cross MS announced on the 24th that it will invest KRW 4.3 billion in expanding its production plant for powder-type hemodialysis products. This investment represents 12.31% of its equity capital, and the project will continue until July 31, 2024.
HLB Science Acquires Bonds Before Maturity After Issuing Convertible Bonds
HLB Science announced on the 24th that it has acquired convertible bonds and bonds before maturity in order to request a partial early redemption from bondholders. The conversion price per share is KRW 2,300, and the amount of bonds acquired is KRW 229,673,850.
① Daewoong acquires a stake in ‘Privatera’, a US partner = Daewoong, the holding company of Daewoong Group, announced on the 24th that it has acquired 3.46 million shares from its US partner, ‘Privatera Acquisition’ for approximately KRW 43.8 billion. The amount is equivalent to 3.4% of Daewoong’s equity capital, and the share after acquisition is 12.63%. Regarding the acquisition of shares in Privetara, Daewoong said it was for the purpose of strengthening partnerships in the global treatment business of its botulinum toxin, ‘Nabota’.
② Handok gives stock options to executives and employees = Handok announced on the 24th that it would grant 7,550 stock options (stock options) to 16 executives and employees. The board of directors voted to grant stock options on the 21st. The event period is from July 21, 2028 to July 20, 2033, and the exercise price is KRW 14,000. After granting stock options, the total number of shares issued is 240,800 shares.
③SK Biopharmaceuticals and SK Life Science signed a supply contract for ‘Cenobamate’ = SK Biopharmaceuticals announced on the 24th that it had signed a supply agreement with SK Bioscience, a subsidiary in the United States, for ‘Cenobamate’, a new drug for the treatment of epilepsy. The contract amount is worth KRW 36.9 billion, which is an internal transaction that cannot be captured in sales based on financial statements.
④ Korea Kolmar Holdings, Vice Chairman of stock purchase Yoon Sang-hyun = The Vice Chairman of Korea Kolmar Holdings, Yoon Sang-hyun, announced on the 24th that he had bought stocks three times on July 19, 20 and 21. The number of shares held by Vice Chairman Yoon is 5,431,012 shares, and after the change, the number of shares is 5,445,158 shares.
⑤Disclosing the results of bond issuance with guarantees worth KRW 14 billion by Dongsung Pharmaceutical = Dongsung Pharmaceutical announced on the 24th that it is issuing bonds with guarantees (BW) worth KRW 14 billion, which was decided on the 20th. A total of 2,381,762 shares were issued following the exercise of warrants, and the purpose of financing was operating funds (KRW 5.5 billion) and debt repayment funds (KRW 8.5 billion) The bond maturity date is July 24, 2028.
⑥Dong-A Socio Holdings·Dong-A ST, announcement of settlement results = Dong-A Socio Holdings and Dong-A ST announced on the 24th that they would reveal their financial results on the 27th. Dong-A Socio Holdings is between January 1 and June 30, 2023, and Dong-A ST is between April 1 and June 30, 2023. It is explained that the results of the settlement disclosed on this day are provisional and may change in the future in the process of review by external auditors.
Dong-A Socio Holdings announces that it will hold a corporate briefing session on the 27th at 4:30 pm It was announced that it would explain the business performance and management status of major related companies in the second quarter of 2023. Dong-A ST also announced that it would hold a company briefing session related to the management performance of the 2nd quarter through a conference call at 3:30 pm on the same day.
⑦Dong-A Socio Holdings, ST Pharm Subsidiary Raw Material Supply Correction Contract Extension = Dong-A Socio Holdings, a subsidiary of ST Pharm, corrected the contract period between July 28, 2023 and August 31, 2023, in response to the customer’s request for an extension to the delivery date, and published it on the 24th. The above contract is a contract to supply raw materials (oligonucleotide) for chronic hepatitis B oligonucleotide treatment, which is currently undergoing global phase 2 clinical trials. ST Pharm is the sole raw material supplier, and the new drug is expected to be commercialized by the end of 2024.
⑧ Acquisition of bonds before maturity after issuing bonds with guarantees by PharmAbcine = PharmAbcine announced on the 24th that it has acquired pre-maturity bonds after issuing bonds with warrants (BW) through the exercise of put options. The exercise price of warrants per share is KRW 6,515, and the amount of bonds acquired is KRW 2 billion.
⑨ Bonds acquired before maturity after issuing convertible bonds = Shillazen announced on the 24th that it had acquired convertible bonds (CB) and acquired bonds before maturity, indicating creditors’ request for early repayment. The conversion price per share is KRW 7,030, and the amount of the acquired bonds is equivalent to KRW 4.4 billion. The acquisition amount is the amount that includes the principal and interest paid, and the conversion price per share was adjusted from 8280 won to 7030 won on January 24, 2023 according to the decrease in the market price.
⑩ Labgenomics, 100% bonus issue resolution. = Labgenomics announced on the 24th that it has decided on a 100% bonus issue, allocating 1 new share to 1 share of common stock. The number of new shares is 37,110,995 ordinary shares, and the reference date for the allocation of new shares is August 8, and the scheduled listing date for new shares is August 28. The KOSDAQ Market Headquarters of the Korea Exchange suspended trading of Labgenomics stock from 3:39 pm until the end of the market on this day.
⑪ ST Pharm, disclosure of settlement results and notice of corporate briefing = ST Pharm announced on the 24th that it would reveal its second quarter results on the 27th from April 1st to June 30th. On the same day, through a video conference call, it was announced that he would hold a company briefing to explain 2Q business results and key issues to analysts in domestic and foreign securities companies. The hours run between 4pm and 4:30pm.
⑫ Nexton Bio, decision to issue convertible bonds = Nexton Bio announced on the 24th that it would issue the 6th privately placed convertible unsecured bond (CB) worth KRW 8 billion. It plans to use KRW 6 billion for operating funds and KRW 2 billion to acquire securities from other corporations. The conversion price is 8885 won. The conversion claim period is between July 26, 2024 and June 26, 2026, and the number of shares issued after conversion is 900,393, which corresponds to 9.72% of the total number of shares issued.
⑬Angook Pharm terminates drug supply contract with Chinese pharmaceutical company = Anguk Pharmaceutical announced on the 24th that it has terminated the supply contract for 300mg of ‘Anicorp’, a drug worth 26.7 billion won, with ‘Sichuan Wanhe Chinese Medicinal Decocting Pieces PLC’. This is an amount equivalent to 18.97% of the recent sales, and the reason for the termination was the failure of the counterparty to fulfill the contract.
⑭ Green Cross MS, invest in expanding production = Green Cross MS announced on the 24th that it would invest 4.3 billion won to expand the production plant for powder type hemodialysis products. This is an amount equivalent to 12.31% of equity capital, and the investment period is until July 31, 2024.
⑮HLB Science, after issuing convertible bonds, acquires bonds before maturity = HLB Science announced on the 24th that it had acquired convertible bonds and acquired bonds before maturity in order to request a partial early redemption of bondholders. The conversion price per share is KRW 2,300, and the amount of bonds acquired is KRW 229,673,850.
#HIT알공 #Daewoong #acquires #stake #Nabota #partner.. #Handok #grants #stock #options
.jpg?fit=300%2C300&ssl=1)
